Clinical Trial Update: Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A completed Phase 4 trial comparing telmisartan and ramipril for effects on renal endothelial dysfunction in patients with type 2 diabetes and hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ramipril (ramipril)
• Telmisartan (Telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2, Hypertension | Phase 4 | Status: COMPLETED